Posted April 2, 2019

FDA Issues Strong Warnings to Sellers of CBD

On March 28, 2019, the FDA issued warning letters to three companies for making unsubstantiated claims about the health benefits of CBD (cannabidiol) products on their websites. The products were promoted for a range of conditions, from chronic pain and skin conditions such as psoriasis, to diabetes, Alzheimer's disease and cancer. The agency also emphasized that CBD is not permitted to be sold as a dietary supplement. Use the links below to see the full warning letter for each company:
  • Advanced Spine and Pain, LLC (dba Relievus) -- Products including CBD Salve, CBD Oil & CBD for Dogs were promoted on the company's website (www.relievuscbdoil.com) with statements such as "CBD Hemp Oil for Pain . . . It can also aid in the treatment of . . . depression, reduce anxiety, and relieve chronic pain and inflammation" and "Cannabidiol Fights Against Cancer."

  • Nutra Pure LLC -- This company's CBD Softgels & Hemp Oil were promoted on https://www.cbdpure.com/ with statements such as "For Alzheimer's patients, CBD is one treatment option that is slowing the progression of that disease," and "CBD has demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms responsible for the pain associated with migraines, fibromyalgia, IBS and other related disorders."

  • PotNetwork Holdings, Inc. -- Products such as Liquid Gold Gummies (Sweet Mix & Sour Mix) and blue CBD Crystals Isolate 1500mg were promoted on the company's website (www.diamondcbd.com) with statements such as "Natural cannabinoids, such as CBD (cannabidiol), have been shown in research to have therapeutic possibilities in helping diabetes."
In a statement about the warnings, FDA Commissioner Scott Gottlieb, M.D. said that he was deeply concerned about companies making unproven claims to treat serious or life-threatening diseases, and that "patients may be misled to forgo otherwise effective, available therapy and opt instead for a product that has no proven value or may cause them serious harm." He warned that the FDA will "use our authorities to take action against companies illegally selling these types of products when they are putting consumers at risk."

The FDA will be holding a public hearing on May 31, 2019, and accepting public comments on safety and regulatory issues concerning the sale of CBD products.

See ConsumerLab's CBD and Hemp Extract Supplements Review for tests of related products.

See related warnings:

Hemp Oil and Cannabidiol (CBD) Marketers Warned by FDA Over Claims

Most CBD Oils, Tinctures, Vapors Labeled Inaccurately

Cannabis Compound Not Permitted in Supplements, FDA Warns

To read the FDA's full statement, use the link below.